Marken Inaugurates New Branch in India
Marken is implementing their stated plan to build the most advanced, fit for purpose clinical Supply chain network to serve the pharmaceutical community. The new India offices build on Marken’s current clinical trial support services and enable the company to grow from its current industry-leading life sciences logistics platform. Marken is expanding their reach throughout India to support their clients rapidly increasing demand for supply chain management services of Active Pharmaceutical Ingredients (API), Investigational Medical Products (IMPs) and Clinical Trial Specimens.
“The expansion of our operations in India enables Marken to better support our clients’ need for regional expertise and temperature controlled supply chain services.” said Wes Wheeler, Marken’s Chief Executive Officer. “We have seen steady growth and demand of our specimen logistics, drug distribution and API supply chain services in India.”
Marken is currently developing a new purpose-built GMP compliant depot in Bangalore due to be complete by the end of 2012. The Bangalore Depot will join Marken’s already operational Argentina, Mexico and Singapore depots offering the full range of temperature controlled storage capabilities including: controlled ambient, refrigerated and frozen as Pharmaceuticals and Medical devices. Each of Marken’s depots provides drug and equipment distribution solutions including: Pick & Pack, relabeling services, reverse logistics, reconciliation and certified destruction. Additionally, the network manages specimen kit distribution, interim specimen storage and management.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025